First results from BladderPath: A randomised trial of MRI versus cystoscopic staging for newly diagnosed bladder cancer

NOVEL THERAPIES FOR HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER.

COMPARISON OF ROBOT-ASSISTED AND OPEN RADICAL CYSTECTOMY IN RECOVERY OF PATIENT-REPORTED AND PERFORMANCE-RELATED MEASURES OF INDEPENDENCEA SECONDARY ANALYSIS OF A RANDOMIZED CLINICAL TRIAL

Industry Symposium

QUIZ

First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study.

Welcome and Introduction

Outcomes of Grade Group 2 and 3 Prostate Cancer on Initial Versus Confirmatory Biopsy: Implications for Active Surveillance: ( M Perrera Eur Urol Focus 2022 Dec )

PACE-A: An International Phase 3 Randomised Controlled Trial (RCT) Comparing Stereotactic Body Radiotherapy (SBRT) to Surgery for Localised Prostate Cancer (LPCa)—Primary Endpoint Analysis

Pooled outcomes of performing freehand transperineal prostate biopsy with the PrecisionPoint Transperineal Access System(BJUI Compass. 2022 Jun)

Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience

Superior Post-Treatment Biopsy Outcomes with High Dose SBRT Compared to High-Dose Conventionally Fractionated IMRT for Clinically Localized Prostate Cancer

Feasibility and safety of radical prostatectomy for oligo- metastatic prostate cancer: theTesting Radical prostatectomy in men with prostate cancer and oligo-Metastases to the bone (TRoMbone) trial

Efficiency and safety of Thalidomide in combination with ADT and Docetaxel

TALAPRO-2: Phase 3 Study of Talazoparib + Enzalutamide Versus Placebo + ENZA as First-Line Treatment in Patients with mCRPC,

Renal cell carcinoma in renal transplant recipients : Is there a role of screening?

Development and Validation of a Nomogram Predicting Intraoperative Adverse Events During Robot-assisted Partial Nephrectomy:

Identifying patients for adjuvant therapy after nephrectomy U capitanio: lancet 2022

LBA66 - IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection + LBA4 - Adjuvant nivolumab plus ipi

Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial (oral asbtract 603)

LBA 8-Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)

Industry Symposium

Industry Symposium 1

Industry Symposium 2